Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventFeb 21, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesFeb 15, 2019View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 14, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2019View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 13, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2019View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 8, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesFeb 7, 2019View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GJan 31, 2019View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GJan 31, 2019View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 24, 2019View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 15, 2019View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 11, 2019View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 10, 2019View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 9, 2019View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJan 8, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 2, 2019View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-93

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information